Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Your mitochondria might hold clues about cancer severity. A new study in The FEBS Journal found that mitochondrial DNA (mtDNA) copy number correlates with the extent of genetic mutations in cancer cells and influences how tumors grow, survive, and respond to chemotherapy — opening a potential new window into cancer management.
Your mitochondria might hold clues about how aggressive a cancer could be. A new multicancer study published in The FEBS Journal by researchers at the Indian Institute of Technology Kharagpur found that mitochondrial DNA (mtDNA) copy number — essentially how many copies of mitochondrial DNA exist within a cell — is closely tied to cancer progression and therapy response.
The research revealed that higher mtDNA copy numbers correlate with greater mutational load in cancer cells, suggesting that mitochondria play a more active role in shaping cancer severity than previously appreciated. Elevated mtDNA copy number also appeared to act as a compensatory signal for impaired mitochondrial function, and was linked to the expression of genes that support tumor growth and survival.
Key Takeaways:
Why it matters: If mtDNA copy number proves to be a reliable biomarker, it could help clinicians better predict cancer aggressiveness and tailor treatment strategies — potentially making it a valuable tool in precision oncology.
